Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program
| Autor: | Donald H. Batts, Alison K. Meagher, Jerome J. Schentag, Craig R. Rayner, Mary C. Birmingham, Susan M. Flavin |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Microbiology (medical)
Adult Male medicine.medical_specialty Adolescent Population Drug resistance chemistry.chemical_compound Anti-Infective Agents Internal medicine Acetamides Drug Resistance Bacterial medicine Endocarditis Humans Drug Interactions education Adverse effect Gram-Positive Bacterial Infections Oxazolidinones Antibacterial agent Aged education.field_of_study business.industry Osteomyelitis Linezolid Middle Aged medicine.disease Drug Resistance Multiple Surgery Infectious Diseases Treatment Outcome chemistry Bacteremia Female business |
| Zdroj: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 36(2) |
| ISSN: | 1537-6591 |
| Popis: | Linezolid was provided for treatment of multidrug-resistant, gram-positive infections through a compassionate-use program. Patients (n=796) received 600 mg of linezolid intravenously or orally every 12 h (828 treatment courses). Bacteremia was present in 46% of infections, endocarditis was present in 10.6%, and line-related infections were present in 31.1%. Other infections included intraabdominal infections (15.1%), complicated skin and skin-structure infections (13.3%), and osteomyelitis (10.7%). Causative pathogens included vancomycin-resistant enterococci (66.3%) and methicillin-resistant staphylococci (22.1%). Clinical intent-to-treat (ITT) outcomes in the evaluable population were as follows: cure, 73.3%; failure, 6.8%; and indeterminate, 19.9%. Microbiological ITT outcomes in evaluable patients were as follows: cure, 82.4%; failure, 14.1%; and indeterminate, 3.5%. At the test of cure assessment, the clinical cure and microbiological success rates were 91.5% and 85.8%, respectively. The most common adverse events possibly related to linezolid use were gastrointestinal disturbances (9.8% of cases), thrombocytopenia (7.4% of cases), decreased hemoglobin/hematocrit levels (4.1% of cases), and cutaneous reactions (4.0% of cases). Linezolid provided high rates of clinical cure and microbiological success in this complicated patient population, with very good overall tolerance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|